Tanzania Diabetes Therapeutics Market Report 2022 to 2030

Tanzania Diabetes Therapeutics Market Analysis

$ 3999

Tanzania's diabetes therapeutics market is expected to witness growth from $58 Mn in 2022 to $129 Mn in 2030 with a CAGR of 10.6% for the forecasted year 2022-30. The rising prevalence and the introduction of novel medications for the treatment of diabetes in Tanzania have resulted in the expansion of the market. The Tanzania diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Kairuki Pharmaceuticals, Keko Pharmaceutical, and Eli Lilly are the major players in the Tanzania diabetes therapeutics market.

ID: IN10TZPH036 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Parul Choudhary

Buy Now

Tanzania Diabetes Therapeutics Market Executive Analysis

Tanzania's diabetes therapeutics market is at around $58 Mn in 2022 and is projected to reach $129 Mn in 2030, exhibiting a CAGR of 10.6% during the forecast period. Tanzania is working toward universal healthcare; in 2020–21, the government allocated $387.9 Mn for the health sector, of which $155.5 Mn will be used for programs that will help the government carry out its plans to improve public health. The sector will receive $0.47 Bn in 2022–2023. Up to 40% of the healthcare budget is provided by international donors as a supplement. Through USAID and the CDC, the US government significantly supports Tanzanian government assistance programs. Only 32% of Tanzanians had health insurance as of 2019. Health insurance coverage is still inadequate. The %age of persons with private health insurance is about 1%.

Over 2 Mn Tanzanians are thought to be suffering from diabetes at this time, according to estimations, which show that the ailment is becoming more common. Tanzania had a diabetes prevalence of 5.2% in 2019 according to the International Diabetes Federation, and if present trends continue, that prevalence is expected to increase to 7.1% by 2045. According to estimations, diabetes is more prevalent in Tanzania's urban than rural areas, with an estimated 8% prevalence in urban and 3% in rural ones.

A group of oral drugs known as SGLT-2 inhibitors reduces blood sugar levels by preventing the kidneys from reabsorbing glucose. A few SGLT-2 inhibitors, including canagliflozin and dapagliflozin, have received Tanzanian approval for use. A class of injectable drugs known as GLP-1 receptor agonists work to lower blood sugar levels by stimulating the release of insulin and inhibiting the release of glucagon. Certain GLP-1 receptor agonists, including semaglutide and dulaglutide, have received Tanzanian approval for use. A type of insulin known as a "biosimilar" is intended to be less expensive while still being similar to already available insulin solutions. Tanzania has authorized the use of biosimilar insulin medicines such as insulin and Basugine.

Tanzania Diabetes Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Over 2 Mn Tanzanians are believed to have diabetes at this time, according to estimates. Diabetes has become more prevalent in Tanzania in recent years. As a result, there is an increasing need for diabetes therapies. Tanzania has made a determined effort to increase awareness of diabetes and how to manage it, which has encouraged more individuals to get their diabetes diagnosed and treated. The Tanzania diabetes therapeutics market has grown as a result. The adoption of novel and cutting-edge diabetic treatments like SGLT-2 inhibitors and GLP-1 receptor agonists has been on the rise in Tanzania. This has resulted in an expansion of the market for diabetic treatments. Tanzania has been spending more on healthcare recently, making it possible for more people to get diabetic medications. The market for diabetic treatments is anticipated to expand as healthcare spending rises.

Market Restraints

Many Tanzanians cannot afford to pay for the appropriate medication and consumables since diabetes therapies can be expensive. This restricts the market for diabetic therapies, especially for more expensive medications. Tanzania's healthcare system is very poor, especially in rural areas. This may reduce the market for diabetic medicines by making it challenging for medical professionals to diagnose and manage diabetes. People may be deterred from getting a diabetes diagnosis or sticking to recommended treatment plans due to cultural or social reasons. These elements can restrict Tanzania's diabetes therapeutics market from expanding.

Competitive Landscape

Key Players

Bajuta Internation (TZA)
Continental Pharma (TZA)
DKT Tanzania (TZA)
Kairuki Pharmaceuticals (TZA)
Keko Pharmaceutical (TZA)
Eli Lilly
Glaxosmithkline
Johnson and Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Takeda Pharmaceutical

Healthcare Policies and Regulatory Landscape

The Tanzania Medications and Medical Devices Authority (TMDA) is a regulatory body in charge of overseeing the effectiveness, safety, and calibre of medications and medical equipment used in Tanzania. The Tanzanian Ministry of Health, Community Development, Gender, Elderly, and Children formed TMDA in 2003. The TMDA oversees a number of tasks, including the registration and licensing of drugs and medical devices, the inspection of manufacturing facilities, post-market monitoring, and the enforcement of laws to guarantee standards are being followed. By making sure that safe and effective medications and medical equipment are available throughout Tanzania, the organization also plays a significant part in boosting public health. Along with performing regulatory duties, the TMDA also offers advice and assistance to the public, healthcare providers, and other stakeholders on matters pertaining to drugs and medical equipment. Information on drug safety, fake medications, and the prudent use of medications are all included. Better health outcomes for the populace are a result of TMDA's contribution to the development of the quality and safety of medications and medical devices in Tanzania. The organization is still working to increase all Tanzanians' access to high-quality medications and medical equipment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Therapeutics Segmentation

By Type (Revenue, USD Billion):

Diabetes 1
Diabetes 2

By Application (Revenue, USD Billion):

Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management

By Drug (Revenue, USD Billion):

Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drug
Combination Drug

By Route of Administration (Revenue, USD Billion):

Oral
Subcutaneous
Intravenous

By Distribution Channel (Revenue, USD Billion):

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Kairuki Pharmaceuticals, Keko Pharmaceutical, and Eli Lilly are the major players in the Tanzania diabetes therapeutics market.

The Tanzania diabetes therapeutics market is expected to grow from $58 Mn in 2022 to $129 Mn in 2030 with a CAGR of 10.6% for the forecasted year 2022-2030.

The Tanzania diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.